Alzheimer disease pathology as a host response

Journal of Neuropathology and Experimental Neurology

Volumn 67, Issue 6, 2008, Pages 523-531

  Castellani, Rudy J ^a,d   Lee, Hyoung Gon ^b   Zhu, Xiongwei ^b   Perry, George ^b,c   Smith, Mark A ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c University of San Antonio   (United States)

^d Division of Neuropathology   (United States)

Author keywords

Alzheimer disease; Amyloid; Tau

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; DIFFUSE LEWY BODY DISEASE; GENETIC POLYMORPHISM; HUMAN; IMMUNE RESPONSE; NEUROFIBRILLARY TANGLE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN STRUCTURE; REVIEW; SENILE PLAQUE; SYNAPSE;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; HUMANS; INFLAMMATION; NEUROFIBRILLARY TANGLES; OXIDATIVE STRESS; SENILE PLAQUES; TAU PROTEINS;

EID: 44649100850     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/NEN.0b013e318177eaf4     Document Type: Review

References (83)

1. Tomlinson BE. Ageing and the dementias. In: Greenfield JB, Adams JH, Duchen L, eds. Greenfield's Neuropathology, 5th ed, Oxford, UK: Oxford University Press, 1992:1284-410
2. Walsh DM, Selkoe DJ. A beta oligomers - A decade of discovery. J Neurochem 2007;101:1172-84
3. Birmingham K, Frantz S. Setback to Alzheimer vaccine studies. Nat Med 2002;8:199-200
4. Golde TE. Disease modifying therapy for AD? J Neurochem 2006;99:689-707
5. Castellani RJ, Zhu X, Lee HG, et al. Neuropathology and treatment of Alzheimer disease: Did we lose the forest for the trees? Expert Rev Neurother 2007;7:473-85
6. Castellani RJ, Lee HG, Zhu X, et al. Neuropathology of Alzheimer disease: Pathognomonic but not pathogenic. Acta Neuropathol (Berl) 2006;111:503-9
7. Alzheimer A. Uber eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeits Psychiat Psychisch-Gerichtlich Med 1907;64:146-48
8. Fuller SC. A study of neurofibrils in dementia paralytica, dementia senilis, chronic alcoholism, cerebral lues and microcephalic idiocy. Am J Insanity 1907;63:415-68
9. Wilkins RH, Brody IA. Alzheimer's disease. Arch Neurol 1969;21:109-10
10. Berrios G. Alzheimer's disease: A conceptual history. Int J Geriatr Psychiatry 1990;5:355-65
11. Maurer K, Maurer U. Alzheimer's Disease: The Life of a Physician and the Career of a Disease. Chichester, West Sussex, UK: Columbia University Press, 2003
12. Kraepelin E. Ein Lehrbuch fur Studierende und Arzte. Leipzig, Germany: Verlag von Johann Ambrosius Barth, 1910
13. Moller HJ, Graeber MB. The case described by Alois Alzheimer in 1911. Historical and conceptual perspectives based on the clinical record and neurohistological sections. Eur Arch Psychiatry Clin Neurosci 1998; 248:111-22
14. Terry RD. The fine structure of neurofibrillary tangles in Alzheimer's disease. J Neuropathol Exp Neurol 1963;22:629-42
15. Kidd M. Paired helical filaments in electron microscopy of Alzheimer's disease. Nature 1963;197:192-93
16. Tellez-Nagel I, Wisniewski HM. Ultrastructure of neurofibrillary tangles in Steele-Richardson-Olszewski syndrome. Arch Neurol 1973;29:324-27
17. Grundke-Iqbal I, Iqbal K, Quinlan M, et al. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 1986;261:6084-89
18. Marx J. Mutation identified as a possible cause of Alzheimer's disease. Science 1991;251:876-77
19. Nash JM. Alzheimer's disease. New insights into its cause lead to new drug strategies. Time 2001;157:80-1, 85
20. Hernandez F, Avila J. Tauopathies. Cell Mol Life Sci 2007;64:2219-33
21. Plattner F, Angelo M, Giese KP. The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J Biol Chem 2006;281:25457-65
22. Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 2007;8:663-72
23. Beljahow S. Pathological changed in the brain in dementia senilis. J Mental Sci 1889;35:261-62
24. Simchowicz T. Sur la signification des plaques seniles et sur la formule senile de l'ecorce cerebrale. Rev Neurol 1924;31:221-27
25. Alzheimer A. Uber eigenartige Krankheitsfalle des spateren Alters. Zbl Ges Neurol Psych 1911;4:356-85
26. Janssen JC, Beck JA, Campbell TA, et al. Early onset familial Alzheimer's disease: Mutation frequency in 31 families. Neurology 2003;60:235-39
27. Finckh U, Muller-Thomsen T, Mann U, et al. High prevalence of pathogenic mutations in patients with early-onset dementia detected by sequence analyses of four different genes. Am J Hum Genet 2000;66:110-17
28. Marinesco G. Sur la structure des plaques dites seniles dans l'ecorce cerebrale des sujets ages et atteints d'affections mentales. Comptes Rendus Seances Soc Biol Fil 1911;70:606-8
29. Divry P. Etude histo-chimique des plaques seniles. J Belge Neurol Psychiatr 1927;27:643-57
30. Luse SA, Smith KR Jr. The ultrastructure of senile plaques. Am J Pathol 1964;44:553-63
31. Glenner GG, Wong CW. Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 1984;122:1131-35
32. Masters CL, Simms G, Weinman NA, et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 1985;82:4245-49
33. Glenner GG. On causative theories in Alzheimer's disease. Hum Pathol 1985;16:433-35
34. Yankner BA. Amyloid and Alzheimer's disease - Cause or effect? Neurobiol Aging 1989;10:470-71; discussion 477-78
35. Joachim CL, Selkoe DJ. The seminal role of beta-amyloid in the pathogenesis of Alzheimer disease. Alzheimer Dis Assoc Disord 1992;6:7-34
36. Vines G. Alzheimer's disease - From cause to cure? Trends Biotechnol 1993;11:49-55
37. Gravina SA, Ho L, Eckman CB, et al. Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J Biol Chem 1995;270:7013-16
38. Younkin SG. Evidence that A beta 42 is the real culprit in Alzheimer's disease. Ann Neurol 1995;37:287-88
39. Crystal HA, Dickson D, Davies P, et al. The relative frequency of "dementia of unknown etiology" increases with age and is nearly 50% in nonagenarians. Arch Neurol 2000;57:713-19
40. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-86
41. Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol 1985;42:1097-105
42. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-59
43. The National Institute on Aging and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol Aging 1997;18:S1-S2
44. Santacruz K, Lewis J, Spires T, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005;309:476-81
45. Jimenez-Escrig A, Rabano A, Guerrero C, et al. New V272A presenilin 1 mutation with very early onset subcortical dementia and parkinsonism. Eur J Neurol 2004;11:663-69
46. Shrimpton AE, Schelper RL, Linke RP, et al. A presenilin 1 mutation (L420R) in a family with early onset Alzheimer disease, seizures and cotton wool plaques, but not spastic paraparesis. Neuropathology 2007;27:228-32
47. Citron M, Oltersdorf T, Haass C, et al. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature 1992;360:672-74
48. Cai XD, Golde TE, Younkin SG. Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. Science 1993;259:514-16
49. Bentahir M, Nyabi O, Verhamme J, et al. Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J Neurochem 2006;96:732-42
50. Kumar-Singh S, Theuns J, Van Broeck B, et al. Mean age-of-onset of familial Alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. Hum Mutat 2006;27:686-95
51. Lee HG, Zhu X, Castellani RJ, et al. Amyloid-beta in Alzheimer disease: The null versus the alternate hypothesis. J Pharmacol Exp Ther 2007; 321:823-29
52. Lorenzo A, Yankner BA. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc Natl Acad Sci U S A 1994;91:12243-47
53. Forloni G, Chiesa R, Smiroldo S, et al. Apoptosis mediated neurotoxicity induced by chronic application of beta amyloid fragment 25-35. Neuroreport 1993;4:523-26
54. Eikelenboom P, Veerhuis R, Scheper W, et al. The significance of neuroinflammation in understanding Alzheimer's disease. J Neural Transm 2006;113:1685-95
55. Mark RJ, Blanc EM, Mattson MP. Amyloid beta-peptide and oxidative cellular injury in Alzheimer's disease. Mol Neurobiol 1996;12:211-24
56. Bandyopadhyay B, Li G, Yin H, Kuret J. Tau aggregation and toxicity in a cell culture model of tauopathy. J Biol Chem 2007;282:16454-64
57. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992;42:631-39
58. Giannakopoulos P, Herrmann FR, Bussiere T, et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology. 2003;60:1495-500
59. Bierer LM, Hof PR, Purohit DP, et al. Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease. Arch Neurol 1995;52:81-88
60. Dickson DW, Crystal HA, Mattiace LA, et al. Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol Aging 1992;13:179-89
61. Berg L, McKeel DW Jr, Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: Relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol 1998;55:326-35
62. Knopman DS, Parisi JE, Salviati A, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol 2003;62:1087-95
63. Snyder EM, Nong Y, Almeida CG, et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 2005;8:1051-58
64. Tanzi RE. The synaptic Abeta hypothesis of Alzheimer disease. Nat Neurosci 2005;8:977-79
65. Lue LF, Kuo YM, Roher AE, et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol. 1999;155:853-62
66. McLean CA, Cherny RA, Fraser FW, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999;46:860-66
67. Wang J, Dickson DW, Trojanowski JQ, Lee VM. The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol 1999;158:328-37
68. Dineley KT, Xia X, Bui D, et al. Accelerated plaque accumulation, associative learning deficits, and up-regulation of alpha 7 nicotinic receptor protein in transgenic mice co-expressing mutant human presenilin 1 and amyloid precursor proteins. J Biol Chem 2002;277:22768-80
69. Jacobsen JS, Wu CC, Redwine JM, et al. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 2006;103:5161-66
70. Lesne S, Koh MT, Kotilinek L, et al. A specific amyloidbeta protein assembly in the brain impairs memory. Nature 2006;440:352-57
71. Smith MA, Hirai K, Hsiao K, et al. Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem 1998;70:2212-15
72. Galvan V, Gorostiza OF, Banwait S, et al. Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664. Proc Natl Acad Sci U S A 2006;103:7130-35
73. Trojanowski JQ, Lee VM. Pathological tau: A loss of normal function or a gain in toxicity? Nat Neurosci 2005;8:1136-37
74. Stokin GB, Lillo C, Falzone TL, et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 2005;307:1282-88
75. Yoshiyama Y, Higuchi M, Zhang B, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007;53:337-51
76. Morsch R, Simon W, Coleman PD. Neurons may live for decades with neurofibrillary tangles. J Neuropathol Exp Neurol 1999;58:188-97
77. Cash AD, Aliev G, Siedlak SL, et al. Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation. Am J Pathol 2003;162:1623-27
78. Nunomura A, Castellani RJ, Zhu X, et al. Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol 2006;65:631-41
79. Mrak RE, Griffin WS. Common inflammatory mechanisms in Lewy body disease and Alzheimer disease. J Neuropathol Exp Neurol 2007;66:683-86
80. Hofman A, Ott A, Breteler MM, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997;349:151-54
81. Akomolafe A, Beiser A, Meigs JB, et al. Diabetes mellitus and risk of developing Alzheimer disease: Results from the Framingham Study. Arch Neurol 2006;63:1551-55
82. Voskarides K, Damianou L, Neocleous V, et al. COL4A3/COL4A4 mutations producing focal segmental glomerulosclerosis and renal failure in thin basement membrane nephropathy. J Am Soc Nephrol 2007;18:3004-16
83. Bielschowsky M. Histopathology of nerve cells. In: Wilder P, eds. Cytology and Cellular Pathology of the Nervous System, Montreal, Canada: Paul B. Hoeber, Inc., 1932:103